Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
International Journal of Medicinal Mushrooms
IF: 1.423 5-Year IF: 1.525 SJR: 0.431 SNIP: 0.661 CiteScore™: 1.38

ISSN Print: 1521-9437
ISSN Online: 1940-4344

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushr.v12.i2.90
pages 185-192

Blood Lymphocyte and Neutrophil Response of Cultured Rainbow Trout, Oncorhynchus mykiss, Administered Varying Dosages of an Oral Medicinal Mushroom-Based Immunomodulator—"Fin-ImmuneTM"

Duane Barker
Fish Health Teaching & Research, Fisheries & Aquaculture Department, Faculty of Science & Technology, Vancouver Island University, Nanaimo, BC V9R 5S5 Canada
John Holliday
Aloha Medicinals, Inc. 2300 Arrowhead Dr., Carson City, NV 89706, USA

ABSTRACT

In a 10-week (May−August 2008) Phase I trial, 840 1+-year-old rainbow trout, Oncorhynchus mykiss, received a commercial oral immunomodulator, Fin-ImmuneTM, at four different dosages (0, 10, 20, and 30 mg/g−1) to evaluate immune response and growth. The overall objective was to determine an optimal dosage of this product for rainbow trout that provides enhanced immunity with maximal growth and health. Biweekly blood samples were taken from 10 randomly selected fish in each tank (30 samples per treatment) to evaluate the duration of enhanced immunity conferred by Fin-ImmuneTM. The immunological assessment included serum white blood cell (lymphocyte and neutrophil) densities and blood hematocrit (packed cell volume %). Of these three variables, only lymphocyte density increased significantly among trout fed Fin-ImmuneTM at 20 and 30 mg/g−1, which peaked at week 6. At week 7, all trout were switched to regular feed (lacking Fin-ImmuneTM), and by week 10, lymphocyte levels decreased among all levels but were still greater than at week 0. There was growth impairment at the highest dose of Fin-ImmuneTM tested (30 mg/g−1), which can be associated with a physiological compensatory mechanism due to a dose-specific threshold level. Thus, our main objective of this Phase I study was achieved: the 20 mg/g−1 dose of Fin-ImmuneTM should be the most efficacious (of those we tested) to use for a Phase II disease-challenge trial.


Articles with similar content:

A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. Extract (Ganopofy) in Patients with Advanced Cancer
International Journal of Medicinal Mushrooms, Vol.4, 2002, issue 3
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.)Lloyd (Aphyllophoromycetideae) Extract in Patients with Type II Diabetes Mellitus
International Journal of Medicinal Mushrooms, Vol.6, 2004, issue 1
Jin Lan, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
A Randomized, Placebo-Controlled, Multicenter Study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in Patients with Advanced Lung Cancer
International Journal of Medicinal Mushrooms, Vol.5, 2003, issue 4
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
Skin Mucus Protein Profile, Immune Parameters, Immune-Related Gene Expression, and Growth Performance of Rainbow Trout (Oncorhynchus mykiss) Fed White Button Mushroom (Agaricus bisporus) Powder
International Journal of Medicinal Mushrooms, Vol.20, 2018, issue 4
Roghieh Safari, Seyed Hossein Hoseinifar, Omid Amiri, Hamed Kolangi Miandare, Ali Shabni
Preclinical Evaluation of Concurrent Medicinal Mushroom-Based Immune-Enhancement Supplementation in Dogs Undergoing Chemotherapy for Various Cancers
International Journal of Medicinal Mushrooms, Vol.11, 2009, issue 2
Sharon Y. West, Marie N. Mullins, Matt P. Cleaver, Britt M. Gianotti